1UO Approval Status
- FDA approved: No
- Brand name: 1UO
- Generic name: uracil
- Previous name: Xyfid
- Company: Cahaba Pharmaceuticals
- Treatment for: Hand-Foot Syndrome
1UO (uracil) is a first-in-class dihydropyrimidine dehydrogenase (DPD) inhibitor in development for the treatment of Hand-Foot Syndrome (HFS), also known as Palmar-Plantar Erythrodysesthesia.
Development Status and FDA Approval Process for 1UO
|Sep 10, 2008||VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid|
|Jul 1, 2008||VioQuest Pharmaceuticals Submits 510(k) Application to FDA for Xyfid, a Novel Topical Agent for the Treatment of Various Skin Disorders|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.